Loading...

We've got a brand new version of Simply Wall St! Try it out

Lotus Ventures

CNSX:J
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
J
CNSX
CA$16M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Lotus Ventures Inc. produces and sells medical marijuana. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
J Share Price and Events
7 Day Returns
5.4%
CNSX:J
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-27.8%
CNSX:J
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
J Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lotus Ventures (J) 5.4% 14.7% 18.2% -27.8% -2.5% -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • J outperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • J underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
J
Industry
5yr Volatility vs Market

J Value

 Is Lotus Ventures undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Lotus Ventures. This is due to cash flow or dividend data being unavailable. The share price is CA$0.195.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lotus Ventures's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lotus Ventures's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:J PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-05-31) in CAD CA$-0.03
CNSX:J Share Price ** CNSX (2019-09-20) in CAD CA$0.2
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lotus Ventures.

CNSX:J PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:J Share Price ÷ EPS (both in CAD)

= 0.2 ÷ -0.03

-6.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lotus Ventures is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Lotus Ventures is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Lotus Ventures's expected growth come at a high price?
Raw Data
CNSX:J PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Lotus Ventures, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Lotus Ventures's assets?
Raw Data
CNSX:J PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-05-31) in CAD CA$0.16
CNSX:J Share Price * CNSX (2019-09-20) in CAD CA$0.2
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:J PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:J Share Price ÷ Book Value per Share (both in CAD)

= 0.2 ÷ 0.16

1.2x

* Primary Listing of Lotus Ventures.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lotus Ventures is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Lotus Ventures's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Lotus Ventures has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

J Future Performance

 How is Lotus Ventures expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lotus Ventures has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lotus Ventures expected to grow at an attractive rate?
  • Unable to compare Lotus Ventures's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Lotus Ventures's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Lotus Ventures's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:J Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:J Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:J Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-05-31 -4 -2
2019-02-28 -3 -3
2018-11-30 -3 -3
2018-08-31 -2 -3
2018-05-31 -1 -2
2018-02-28 -1 -2
2017-11-30 -1 -1
2017-08-31 -1 -1
2017-05-31 -1 -1
2017-02-28 -1 -1
2016-11-30 -1 -1
2016-08-31 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Lotus Ventures is high growth as no earnings estimate data is available.
  • Unable to determine if Lotus Ventures is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:J Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Lotus Ventures Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:J Past Financials Data
Date (Data in CAD Millions) EPS *
2019-05-31 -0.03
2019-02-28 -0.04
2018-11-30 -0.05
2018-08-31 -0.05
2018-05-31 -0.05
2018-02-28 -0.04
2017-11-30 -0.03
2017-08-31 -0.02
2017-05-31 -0.02
2017-02-28 -0.02
2016-11-30 -0.02
2016-08-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Lotus Ventures will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of J’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Lotus Ventures's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Lotus Ventures's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Lotus Ventures's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lotus Ventures has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

J Past Performance

  How has Lotus Ventures performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lotus Ventures's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Lotus Ventures does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Lotus Ventures's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Lotus Ventures's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Lotus Ventures's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lotus Ventures Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:J Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-05-31 -2.22 2.16
2019-02-28 -2.79 2.74
2018-11-30 -2.66 2.62
2018-08-31 -2.50 2.46
2018-05-31 -2.42 2.38
2018-02-28 -1.59 1.56
2017-11-30 -1.26 1.22
2017-08-31 -0.72 0.68
2017-05-31 -0.69 0.64 0.00
2017-02-28 -0.60 0.56 0.00
2016-11-30 -0.64 0.60 0.00
2016-08-31 -0.81 0.78 0.00
2016-05-31 -0.80 0.74 0.00
2016-02-29 -0.69 0.64 0.00
2015-11-30 -0.76 0.70 0.00
2015-08-31 -0.54 0.45 0.01
2015-05-31 -0.51 0.45 0.02
2014-08-31 -0.19 0.17 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Lotus Ventures has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Lotus Ventures has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Lotus Ventures improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Lotus Ventures's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lotus Ventures has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

J Health

 How is Lotus Ventures's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lotus Ventures's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Lotus Ventures's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Lotus Ventures has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Lotus Ventures's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Lotus Ventures has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lotus Ventures Company Filings, last reported 3 months ago.

CNSX:J Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-05-31 13.41 0.00 0.54
2019-02-28 12.01 0.00 0.62
2018-11-30 12.48 0.00 3.28
2018-08-31 7.62 0.00 1.74
2018-05-31 7.90 0.00 5.33
2018-02-28 8.20 0.00 6.49
2017-11-30 2.47 0.00 1.85
2017-08-31 2.45 0.00 2.15
2017-05-31 0.49 0.00 0.17
2017-02-28 0.72 0.00 0.43
2016-11-30 0.76 0.00 0.50
2016-08-31 0.34 0.00 0.14
2016-05-31 0.50 0.00 0.20
2016-02-29 0.31 0.00 0.20
2015-11-30 0.19 0.00 0.09
2015-08-31 0.26 0.00 0.23
2015-05-31 0.27 0.00 0.17
2014-08-31 0.18 0.00 0.13
  • Lotus Ventures has no debt.
  • Lotus Ventures currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Lotus Ventures has less than a year of cash runway based on current free cash flow.
  • Lotus Ventures has less than a year of cash runway if free cash flow continues to grow at historical rates of 106.3% each year.
X
Financial health checks
We assess Lotus Ventures's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lotus Ventures has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

J Dividends

 What is Lotus Ventures's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Lotus Ventures dividends.
If you bought CA$2,000 of Lotus Ventures shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Lotus Ventures's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lotus Ventures's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:J Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Lotus Ventures has not reported any payouts.
  • Unable to verify if Lotus Ventures's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Lotus Ventures's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Lotus Ventures has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Lotus Ventures's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lotus Ventures afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lotus Ventures has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

J Management

 What is the CEO of Lotus Ventures's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dale McClanaghan
COMPENSATION CA$144,500
AGE 63
TENURE AS CEO 4.8 years
CEO Bio

Mr. Dale Bernard McClanaghan, MBA has been the Chief Executive Officer and President of Lotus Ventures Inc. since November 27, 2014. Mr. McClanaghan has been the Chief Executive Officer and President of BCM Resources Corp. since February 16, 2005. He serves as President of McClanaghan & Associates Consulting Ltd. Mr. McClanaghan has been the Chief Financial Officer of Inland Explorations Ltd. since December 2006. He has been the President of Dale McClanaghan Consulting Ltd. since January 2002. He served as Chief Executive Officer & President of Adrian Resources Ltd., and Van City Enterprises Ltd. He served as Corporate Banker at Bank of Montreal. Mr. McClanaghan served as the Chief Executive Officer at Strachan Resources Ltd. He served as the Chief Executive Officer and President of Petaquilla Minerals Ltd. from April 2004 to December 2004. From May 1995 to January 2002, he served as Chief Executive Officer of VanCity Enterprises Ltd. He has been a Director of BCM Resources Corp. since February 16, 2005 and Inland Explorations Ltd. since December 2006. He served as a Director of Petaquilla Minerals Ltd. since April 16, 2004. He served as a Director of Strachan Resources Ltd. He served as a Director of Adrian Resources Ltd., from April 2004 to December 2004. He served as President of the Vancouver Civic Non-Partisan Association from August 2001 to March 2004. He has been Director of Lotus Ventures Inc. since July 4, 2014. He has been a Member of the NPA Board of Directors since 1989. He has also been active on a number of community boards including; Member of Board of Directors of Langara College, Vancouver City Planning Commission, Dr. Peter Aids Foundation, Katherine Sandford Housing Society and the Vancouver Heritage Foundation. Mr. McClanaghan holds a Master of Business Administration from the University of British Columbia.

CEO Compensation
  • Dale's compensation has increased whilst company is loss making.
  • Dale's remuneration is about average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Lotus Ventures management team in years:

2.6
Average Tenure
63
Average Age
  • The tenure for the Lotus Ventures management team is about average.
Management Team

Dale McClanaghan

TITLE
CEO, President & Director
COMPENSATION
CA$145K
AGE
63
TENURE
4.8 yrs

Carl Correia

TITLE
COO & Director
COMPENSATION
CA$139K
AGE
39
TENURE
4.8 yrs

Gary Mathiesen

TITLE
AGE
65
TENURE
0.3 yrs

Maurice Creagh

TITLE
CFO & Director
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Lotus Ventures board of directors in years:

0.5
Average Tenure
39
Average Age
  • The average tenure for the Lotus Ventures board of directors is less than 3 years, this suggests a new board.
Board of Directors

Dale McClanaghan

TITLE
CEO, President & Director
COMPENSATION
CA$145K
AGE
63
TENURE
14.2 yrs

Carl Correia

TITLE
COO & Director
COMPENSATION
CA$139K
AGE
39
TENURE
3.9 yrs

Maurice Creagh

TITLE
CFO & Director
TENURE
0.3 yrs

Simon Davie

TITLE
Director
TENURE
0.5 yrs

Jeff Tung

TITLE
Director
AGE
33
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Lotus Ventures individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
10. Sep 19 Sell Dale McClanaghan Individual 10. Sep 19 10. Sep 19 -10,000 CA$0.21 CA$-2,050
23. Aug 19 Buy Dale McClanaghan Individual 22. Aug 19 22. Aug 19 20,000 CA$0.18 CA$3,500
16. Mar 19 Sell Stephen Mathiesen Individual 13. Mar 19 13. Mar 19 -8,500 CA$0.42 CA$-3,535
16. Mar 19 Sell Gary Mathiesen Individual 11. Mar 19 14. Mar 19 -79,500 CA$0.42 CA$-30,236
09. Mar 19 Sell Gary Mathiesen Individual 05. Mar 19 05. Mar 19 -3,000 CA$0.34 CA$-1,020
18. Feb 19 Sell Gary Mathiesen Individual 13. Feb 19 13. Feb 19 -11,000 CA$0.35 CA$-3,627
18. Feb 19 Buy Gary Mathiesen Individual 13. Feb 19 13. Feb 19 10,000 CA$0.34 CA$3,400
07. Feb 19 Sell Gary Mathiesen Individual 05. Feb 19 05. Feb 19 -50,000 CA$0.34 CA$-16,750
29. Nov 18 Buy Dale McClanaghan Individual 26. Nov 18 26. Nov 18 8,000 CA$0.20 CA$1,600
15. Nov 18 Buy McClanaghan and Associates Consulting Ltd. Company 12. Nov 18 14. Nov 18 4,000 CA$0.22 CA$830
09. Nov 18 Buy McClanaghan and Associates Consulting Ltd. Company 07. Nov 18 07. Nov 18 9,000 CA$0.20 CA$1,800
06. Nov 18 Sell McClanaghan and Associates Consulting Ltd. Company 31. Oct 18 31. Oct 18 -39,000 CA$0.23 CA$-8,775
06. Nov 18 Buy McClanaghan and Associates Consulting Ltd. Company 02. Nov 18 06. Nov 18 27,500 CA$0.22 CA$5,920
31. Oct 18 Buy McClanaghan and Associates Consulting Ltd. Company 26. Oct 18 26. Oct 18 300,000 CA$0.25 CA$75,000
31. Oct 18 Sell McClanaghan and Associates Consulting Ltd. Company 18. Oct 18 18. Oct 18 -213,000 CA$0.24 CA$-51,972
16. Oct 18 Buy McClanaghan and Associates Consulting Ltd. Company 15. Oct 18 15. Oct 18 600,000 CA$0.25 CA$150,000
X
Management checks
We assess Lotus Ventures's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lotus Ventures has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

J News

Simply Wall St News

Did You Manage To Avoid Lotus Ventures's (CNSX:J) 50% Share Price Drop?

Investors will be hoping that Lotus Ventures can make progress and gain better traction for the business, before it runs low on cash. … But since the share price has dived -50% in the last year, it looks like some investors think it's time to abandon ship, so to speak. … A Different Perspective The last twelve months weren't great for Lotus Ventures shares, which cost holders 50%, while the market was up about 0.6%.

Simply Wall St -

Does Market Volatility Impact Lotus Ventures Inc.'s (CNSX:J) Share Price?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … This is above 1, so historically its share price has been influenced by the broader volatility of the stock market. … What this means for you: Since Lotus Ventures has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

Lotus Ventures Inc. (CNSX:J): What Does Its Beta Value Mean For Your Portfolio?

(CNSX:J), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).

Simply Wall St -

What You Must Know About Lotus Ventures Inc's (CNSX:J) Major Investors

In this analysis, my focus will be on developing a perspective on Lotus Ventures Inc’s (CNSX:J) latest ownership structure, a less discussed, but important factor. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Check out our latest analysis for Lotus Ventures

Simply Wall St -

J Company Info

Description

Lotus Ventures Inc. produces and sells medical marijuana. The company is based in Vancouver, Canada.

Details
Name: Lotus Ventures Inc.
J
Exchange: CNSX
Founded:
CA$16,102,085
82,574,799
Website: http://lotuscannabis.ca
Address: Lotus Ventures Inc.
1030 West Georgia Street,
Suite 1010,
Vancouver,
British Columbia, V6E 2Y3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX J Common Shares Canadian National Stock Exchange CA CAD 23. Oct 2015
OTCPK LTTS.F Common Shares Pink Sheets LLC US USD 23. Oct 2015
DB LV9 Common Shares Deutsche Boerse AG DE EUR 23. Oct 2015
Number of employees
Current staff
Staff numbers
0
Lotus Ventures employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:33
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/30
Last earnings reported: 2019/05/31
Last annual earnings reported: 2018/08/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.